🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Exciting Update from EV301 trial! 🚀EV maintains survival benefit after ~2 years of follow-up. BUT: Who benefits most from EV?🎯 Our data suggest NECTIN4 as a promising predictive biomarker! OncoAlert UroToday.com Markus Eckstein Viktor Grünwald aacrjournals.org/clincancerres/… #oncology

True Champions.

Great to see the work of my first PhD student finally published in Science Advances, extending our data-based modeling framework to study a network of proliferating cell populations in chronic inflammation. DRFZ IEO_Bonn ImmunoSensation @HCM_Bonn science.org/doi/10.1126/sc…

Excellent presentation by Gonzalo at the Single Domain Antibodies Meeting 2023 in Paris on his generic #CRISPR #CAR T cell platform! Important tool to improve #cellular #cancer #immunotherapies Rheinische Friedrich-Wilhelms-Universität Bonn⁩ ⁦ImmunoSensation⁩ ⁦@MSSOabcd⁩ ⁦IEO_GloddeLab⁩

Congratulations to Niklas Klümper from IEO_Bonn & Dept. of. Urology Uniklinik Bonn for this prestigious research award DGU Kongress. Happy to support & mentor. Perfect example for the success of #clinicianscientist programs DGU Rheinische Friedrich-Wilhelms-Universität Bonn BONFOR @BMBF_Bund ACCENT

All true and indeed, we will not give up. We need #innovation for our (cancer) patients. @MSSOabcd is a nice example for a program supporting #cancer #research. Impressive young scientists & interdisciplinary spirit #CIOabcd. Thanks for funding Deutsche Krebshilfe

Combo or sequence in #mRCC - odd question? #NIVOSWITCH tested switch-maintenance in mRCC 👉 ORR IO/TKI: 20 vs. 52% 👉 PFS IO/TKI: 3.0 vs. 11.9 mo 👉 2y-OS 64 vs. 66% 👉 supports use of IO-combos Tom Powles Toni Choueiri, MD Sumanta K. Pal, MD, FASCO Enrique Grande sciencedirect.com/science/articl…

It is so amazing. What a game changer

Verkaufsausstellung zugunsten von LebensWert: Mit einer Vernissage startet morgen im #CIO der #Uniklinik #Köln eine Ausstellung mit Werken des Kölner Künstlers Rudolf Watzlawik. Der Erlös kommt dem Verein LebensWert für krebskranke Patienten zugute. uk-koeln.de/uniklinik-koel…

Thanks Viktor Grünwald for highlighting our work on the value of NECTIN4 status to predict EV response at a stellar symposium with Petros Grivas Enrique Grande joaquim bellmunt at ESMO - Eur. Oncology aacrjournals.org/clincancerres/… OncoAlert UroToday.com Clinical Cancer Research Predictive biomarkers are needed !

In three Phase III trials (mUC: IMvigor211, mRCC: IMmotion151, NSCLC: OAK) immunotherapy prolonged OS when baseline serum albumin was >35g/L -> Prediction of less immune fitness via simple albumin measurement?onlinelibrary.wiley.com/doi/10.1002/ct… OncoAlert Clinical & Translational Immunology Tobias Bald IEO_Bonn

Great to see EV+PEM being approved for 1L mUC based on EV-302 Tom Powles!🎉To further improve outcomes precision medicine is needed. Great overview of future directions by Matt Galsky🎯NECTIN4 again discussed to predict EV outcomes OncoAlert UroToday.com link.springer.com/article/10.100…

Congrats to Emma Grace Bawden & Thomas Gebhardt to this amazing work on #melanoma #immunity. Fantastic collaboration within Bonn & Melbourne Research and Graduate School. Thanks to DFG public | @[email protected] University of Melbourne Rheinische Friedrich-Wilhelms-Universität Bonn

NECTIN4 amplification predicts response to Enfortumab vedotin in mUC! It occurs frequently across solid tumors (app. 25% of mUC)➡️potential tumor-agnostic biomarker for NECTIN4-targeting therapies! Happy to share our poster K17 ASCO #GU24! Markus Eckstein OncoAlert UroToday.com

Exciting study reveals correlation between Trop2 target expression and anti-Trop2 ADC SG response in TNBC! Journal of Clinical Oncology The ASCO Post Paolo Tarantino Membranous target gene expression crucial for ADC efficacy! ➡️ well-established for Her2, Nectin4, and Folr1 ! We need to consider the

Final results from #ASCENT in Journal of Clinical Oncology. SG demonstrates huge OS benefits in patients with triple negative #breast #cancer. Although benefit present in all subgroups, there is an incremental benefit dependent on TROP2 surface expression 🏄‍♂️! 👉 another piece of the puzzle‼️🎯

Congrats to the 4 lead investigators Chun-Pu, Pierre, Astrid and Georgi from my lab The Netherlands Cancer Institute Oncode Institute + collaborators, reporting today in Cancer Cell several genes whose inactivation generates fitter immune T cells for enhanced tumor killing. cell.com/cancer-cell/fu…

Proud to be the mentor of Niklas Klümper in UroAgeCare funded by DFG public | @[email protected]. Now, the work on NECTIN4 amplifications predicting response to enfortumab vedotin in patients with mUC is published in Journal of Clinical Oncology! Underscores the importance of #clinician #scientist #programmes.